Associations between human leukocyte antigen C locus polymorphism and psoriatic arthritis in populations of European and Middle Eastern descent: a meta-analysis

Lin-Nan Shao,a Ni Wang,a Shi-Hang Zhou,a Zi Wangb

From the aBlood Group, Balian Blood Center, Dalian, China; bDepartment of Sports Medicine, Dalian Municipal Central Hospital, Dalian, China

BACKGROUND: Gene-disease association between human leukocyte antigen (HLA)-C locus polymorphism and psoriatic arthritis (PsA) remains controversial.

OBJECTIVE: Evaluate the relationship between HLA-C locus polymorphism and PsA in populations of European and Middle Eastern descent.

SEARCH METHODS: PubMed, PMC, Elsevier and Google Scholar databases from 1980 to January 2020. The search was limited to articles in English.

SELECTION CRITERIA: Case-control studies (with unrelated participants) that had allele/genotype data on the association between HLA-C locus polymorphism and PsA susceptibility.

DATA COLLECTION AND ANALYSIS: Two investigators searched independently in searching the literature. Disagreements were resolved by discussion and consultation with a third researcher. The Q-Genie tool was used to assess the quality of articles.

RESULTS: Twenty-five studies met the inclusion criteria. At the allelic level, three alleles were associated with an increased risk of PsA and five were associated with a reduced risk. At the phenotypic level, four alleles were associated with increased risk of PsA and three were associated with a reduced risk. At both the allelic and phenotypic levels, the results revealed that HLA-C*04 played a protective role in PsA (The pooled odds ratio [OR] is 0.66 for allelic level and 0.63 for phenotypic level), while HLA-C*02, *06 and *12 increased the risk of suffering from PsA (The pooled ORs of C*02, *06 and *12 are 2.21, 2.63 and 1.49 for allelic level, and 1.79, 2.96 and 2.25 for phenotypic level, respectively).

CONCLUSION: The pooled results showed a significant association between PsA and the HLA-C gene in populations of European and Middle Eastern descent. At both the allelic and phenotypic levels, the HLA-C*02, *06 and *12 may contribute to susceptibility to PsA, while HLA-C*04 may confer a protective role against PsA.

REGISTRATION: Not registered.

CONFLICT OF INTEREST: None.
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy characterized by arthritis, enthesitis, and spondylitis. The estimated global prevalence of PsA is 133 per 100,000 subjects, and 0.19% in Europe and 0.01% in the Middle East. In addition, PsA occurs in up to 30% of patients with psoriasis. Thus, it can be considered a “disease within a disease”. PsA is significantly associated with mortality and the estimated cost to healthcare systems is equivalent to that of rheumatoid arthritis. The precise etiology of PsA is unclear, but accumulating evidence suggests a key role for genetic factors in PsA with respect to disease susceptibility and expression.

The human leukocyte antigen (HLA) is a polymorphic genetic system encoding the genes involved in the immune response. HLA variation plays a major role in susceptibility to infectious and autoimmune diseases. Various studies have demonstrated a relationship between HLA-C polymorphism and susceptibility to PsA. Reports of an association between the presence of the HLA-C*06 allele and PsA are consistent; for example, Chandran et al showed that the frequency of HLA-C*06 was significantly increased ($P<0.001$) in PsA patients compared with controls, with an odds ratio (OR) of 1.72. In contrast, studies from some populations indicated no association between HLA-C*06 and PsA; for example, Grubić et al demonstrated that the difference in distribution of HLA-C*06 in both PsA patients and controls was not significant. Therefore, the association between HLA-C locus polymorphism and PsA remains controversial. We conducted this meta-analysis to estimate the precise association between HLA-C locus polymorphism and PsA in Caucasian populations.

**METHODS**

**Study search strategy**

We conducted a systematic search of studies on the association between HLA-C polymorphism and PsA susceptibility using the PubMed, PMC, Elsevier and Google Scholar databases from 1980 to January 2020, using the search term “(((psoriatic arthritis[MeSH Terms]) OR psoriatic arthritis[Title/Abstract]) OR HLA-C[Title/Abstract]) AND (((HLA-Cw[Title/Abstract]) OR HLA-C[MeSH Terms]) OR HLA-C[Title/Abstract])”. Search results were limited to studies in English.

Inclusion criteria were defined as follows: case-control studies (with unrelated participants) that had allele/genotype data that evaluated the association between HLA-C locus polymorphism and PsA susceptibility. Moreover, studies reporting the results of different subpopulations were treated as separate studies with respective OR and 95% CI values assessed independently.

Studies were excluded if they evaluated subjects not of European and Middle Eastern descent, the study was based on family or sibling pairs, the allele/genotype frequencies or numbers were not given, or review articles, abstracts and books. When the same patient population was reported in numerous publications, only the most complete or recent study was used.

**Data extraction**

Using the criteria described above, each manuscript was screened, assessed for quality and data were extracted by two investigators independently with cross-checking. Disagreements were resolved by discussion and consultation with a third researcher. The following data were extracted: first author, year of publication, ethnicity, detection method and the numbers of cases and controls. Eligibility of studies was determined using the Q-Genie tool. Studies with scores ≤35 were of low-quality, those scoring between 36 and 45 were of moderate quality and those >45 were high-quality. Genetic data were classified as either allelic or phenotypic.

**Statistical analysis**

Data extracted from eligible studies were processed prior to conducting the meta-analysis. Frequency data were translated into numerical values by multiplying the number of samples with values, and numerical data were extracted directly. An $I^2$ test was used to evaluate heterogeneity among studies. A fixed-effects model was used if $I^2<50\%$, otherwise, a random-effects model was used. $P$ values of less than .05 were considered statistically significant. Random-effects model-based subgroup analysis stratified by quality was performed to determine the source of heterogeneity. If quality was not able to explain heterogeneity, univariate random-effects meta-regression was used to explore the heterogeneity, such as publication year, number of cases and case/control ratio. Potential publication bias was intuitively evaluated using funnel plots. Meanwhile, bias was estimated using an Egger’s test. Meta-analysis was conducted using STATA 12.0 software.

**RESULTS**

**Included studies**

A total of 153 studies were identified after initial review using the search strategies previously described, and 24 articles were retained for meta-analysis (Figure 1). After accessing the full-text of the eligible stud-
ies, one study\(^9\) was split into two studies because it contained data for two different subpopulations. Thus, 25 studies were included (Table 1).

**Results of meta-analysis**
The meta-analyses of OR, 95% CI and \(I^2\)-statistics between HLA-C polymorphism and PsA are presented in Table 2. At the allelic level, eight alleles had a significant association with PsA. HLA-C*02, *06 and *12 were associated with an increased risk of PsA, while HLA-C*03, *04, *05, *07 and *16 had a decreased risk of PsA. At the phenotypic level, seven phenotypes had a significant association with PsA. Positive associations were observed for HLA-C*01, *02, *06 and *12. Negative associations were observed for HLA-C*04, *14 and *15. At both the allelic and phenotypic levels, the results showed that HLA-C*04 played a protective role in PsA while HLA-C*02, *06 and *12 increased the risk for PsA (Figures 2 and 3).

**Subgroup analysis and heterogeneity**
When more than four studies had been published, a subgroup analysis of quality was performed (Table 2). Sufficient numbers of high- and moderate-quality studies were included and thus, subgroup analysis of low-quality studies is not shown. HLA-C*02 and *06 at allelic level and HLA-C*06 at the phenotypic level were associated with an increased risk of PsA in both high- and moderate-quality subgroups. HLA-C*03, *04 and *07 at the allelic level and HLA-*04 and *07 at the phenotypic level were associated with a decreased risk of PsA in both subgroups. Moreover, the quality explained the heterogeneity observed in HLA-C*07 at the allelic and phenotypic levels because heterogeneity of the subgroups was reduced to zero. Except for the heterogeneity of HLA-C*07 at the allelic level, sources of heterogeneity for the other studies were explored using univariate meta-regression. However, year of publication, size of case and case/control ratio were not statistically correlated with heterogeneity (\(P>.05\)).

**Publication bias**
The funnel plots showed no evidence of obvious asymmetry. When assessed by the Egger’s test, no publication bias was found (\(P>.05\)).

**DISCUSSION**
PsA is a chronic immune-mediated inflammatory disorder whereby environmental factors trigger disease in genetically susceptible individuals, with multiple genetic factors contributing to disease susceptibility. PsA is associated with the presence of psoriasis and has a serious impact on the quality of life of patients, an impact that has been demonstrated as lower than that of patients with psoriasis alone.\(^1\) Several articles demonstrated a correlation between HLA-C and PsA. The most intriguing allele, HLA-C*06, has already been described in a number of populations with susceptibility to PsA, such as native populations of the Czech Republic,\(^20\) Spain,\(^21,22\) Great Britain,\(^9\) Poland,\(^23\) Romania,\(^24\) Sweden\(^25\) and Newfoundland.\(^19\) Furthermore, genome-wide association studies have confirmed that the HLA-C region is involved in susceptibility to PsA in populations of European and Middle Eastern descent.\(^1,39,40\) The pathogenesis of PsA embraces both innate immunity and a major histocompatibility complex class I (MHC class I) T-cell related cytotoxic response. Additionally, PsA could be viewed as a “MHC-I-opathy” due to interactions between MHC class I alleles modifying expression and tissue specific factors.\(^41\) Nevertheless, no association was found between HLA-C*06 and PsA in the Croatian population\(^14\) or in Canadians from Ontario.\(^19\)

It is noteworthy that HLA-C*06 has been shown to be related to PsA in patients with Type I psoriasis in young-onset disease (≤40 years), but not with Type II psoriasis with onset older than 40 years.\(^9\) Recent studies have

---

**Figure 1.** Study selection diagram. HLA: human leukocyte antigen, PsA: psoriatic arthritis.
Figure 2. Forest plots of the association between HLA-C allele frequencies and psoriatic arthritis (Study a: HLA-C*02; Study b: HLA-C*04; Study c: HLA-C*06; Study d: HLA-C*12).

Figure 3. Forest plots of the association between HLA-C phenotype frequencies and psoriatic arthritis (Study a: HLA-C*02; Study b: HLA-C*04; Study c: HLA-C*06; Study d: HLA-C*12).
Table 1. Characteristics of the 25 studies included in the meta-analysis.

| First author     | Year | Sample size | Typing method | HLA-C/Cw | Data form | Q-Genie |
|------------------|------|-------------|---------------|----------|-----------|---------|
|                  | Cases | Controls    |               |          |           |         |
| Murray           | 1980  | 52          | 126           | Serology  | 6         | P       |
| Woodrow          | 1985  | 50          | 115           | Serology  | 1, 2, 3, 4, 5, 6, 7 | P       |
| López-Larrea     | 1990  | 104         | 109           | Serology  | 4, 5, 6   | P       |
| González         | 1999  | 65          | 177           | SSOP     | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16 | A       |
| Gladman          | 1999  | 94          | 100           | SSOP     | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17 | A       |
| Martin           | 2002  | 355         | 295           | SSP      | 06        | A       |
| González         | 2002  | 81          | 110           | SSP      | 06        | P       |
| Al-Heresh        | 2002  | 124         | 101           | SSP      | 06        | P       |
| Alenius          | 2002  | 84          | 70            | SSP      | 03, 06    | P       |
| Martínez-Borra   | 2003  | 74          | 104           | SSP      | 06        | P       |
| Grubić           | 2004  | 58          | 157           | SSP      | 02, 06, 07 | A       |
| Dobosz           | 2005  | 41          | 80            | SSP      | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17 | A       |
| Rahman           | 2005  | 103         | 105           | SSP      | 06        | P       |
| Rahman           | 2005  | 202         | 100           | SSP      | 06        | P       |
| Holm             | 2005  | 65          | 371           | -        | 06        | P       |
| Queiro           | 2006  | 100         | 177           | SSOP     | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16 | A       |
| Ho               | 2008  | 453         | 166           | SSP      | 06        | P       |
| Queiro           | 2008  | 120         | 170           | SSP      | 06        | P       |
| Fojtíková        | 2009  | 100         | 94            | SSP      | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17 | A       |
| Popa             | 2011  | 81          | 124           | SSP      | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17 | P       |
| Winchester       | 2012  | 359         | 1000          | SBT      | 01, 02, 04, 05, 06, 07, 12 | P       |
| Cibulova         | 2013  | 101         | 99            | SSP      | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17 | A       |
| Chandran         | 2013  | 678         | 688           | SSOP     | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17 | P       |
| Sokolik          | 2014  | 50          | 123           | SSP      | 01, 02, 03, 04, 05, 06, 07, 08, 12, 14, 15, 16, 17 | A       |
| Queiro           | 2014  | 110         | 110           | SSP      | 06        | P       |

SSOP: sequence-specific oligonucleotide probes, SSP: sequence-specific primers, SBT: Sequence-based typing, A: allele counts or frequencies, P: phenotype counts or frequencies, Q-Genie: quality of genetic studies, L: low-quality study, M: moderate-quality study, H: high-quality study, C/Cw: serology/molecular nomenclature.
Table 2. Associations between HLA-C polymorphism and psoriatic arthritis and subgroup analyses based on quality at allelic and phenotypic levels.

| HLA-C/Cw | Eligible studies | Heterogeneity | Association | Egger’s Test |
|----------|-----------------|---------------|-------------|--------------|
|          |                 | P             | I² (%)      | P            | OR 95% CI   | t            |
| 01       | Allele          | 7             | 0.965       | 0.0          | 0.533        | 1.119        | 0.785-1.596  | -0.77        |
| 02       | Allele          | 8             | 0.406       | 3.1          | <0.001       | 2.208        | 1.594-3.060  | -1.06        |
| 03       | Allele          | 7             | 0.952       | 0.0          | 0.004        | 0.673        | 0.512-0.884  | -0.79        |
| 04       | Allele          | 7             | 0.457       | 0.0          | 0.001        | 0.663        | 0.519-0.846  | 0.35         |
| 05       | Allele          | 7             | 0.954       | 0.0          | 0.006        | 0.609        | 0.428-0.866  | 0.99         |
| 06       | Allele          | 9             | 0.073       | 44.2         | <0.001       | 2.631        | 2.200-3.146  | 1.07         |
| 07       | Allele          | 8             | 0.054       | 49.3         | <0.001       | 0.710        | 0.597-0.843  | 0.39         |
| 08       | Allele          | 7             | 0.048       | 52.7         | 0.956        | 0.978        | 0.436-2.190  | -0.97        |
| 12       | Allele          | 7             | 0.435       | 0.0          | 0.010        | 1.490        | 1.102-2.015  | -0.55        |
| 14       | Allele          | 7             | 0.988       | 0.0          | 0.945        | 0.979        | 0.529-1.809  | 1.22         |
| 15       | Allele          | 7             | 0.987       | 0.0          | 0.515        | 0.828        | 0.469-1.462  | 0.81         |
| 16       | Allele          | 7             | 0.558       | 0.0          | 0.010        | 0.503        | 0.299-0.846  | -1.06        |
| 17       | Allele          | 5             | 0.848       | 0.0          | 0.058        | 0.376        | 0.142-0.993  | -2.24        |
| 18       | Allele          | 2             | 0.188       | 42.2         | 0.707        | 1.404        | 0.239-8.229  | -            |
| 01/1     | Phenotype       | 4             | 0.842       | 0.0          | <0.001       | 1.952        | 1.489-2.560  | -1.50        |
| 02/2     | Phenotype       | 4             | 0.045       | 62.8         | 0.023        | 1.791        | 1.084-2.959  | 0.09         |
| 03/3     | Phenotype       | 4             | 0.023       | 68.5         | 0.673        | 0.872        | 0.462-1.645  | 0.93         |
| 04/4     | Phenotype       | 5             | 0.524       | 0.0          | <0.001       | 0.630        | 0.523-0.760  | -0.63        |
| 05/5     | Phenotype       | 5             | 0.006       | 72.6         | 0.115        | 0.653        | 0.384-1.109  | -1.27        |
| 06/6     | Phenotype       | 16            | <0.001      | 70.7         | <0.001       | 2.956        | 2.298-3.804  | 2.62         |
| 07/7     | Phenotype       | 4             | <0.001      | 85.9         | 0.330        | 0.789        | 0.489-1.272  | -0.25        |
| 08       | Phenotype       | 2             | 0.855       | 0.0          | 0.428        | 0.861        | 0.596-1.246  | -            |
| 12       | Phenotype       | 3             | 0.170       | 43.6         | <0.001       | 2.253        | 1.781-2.852  | -3.46        |
| 14       | Phenotype       | 2             | 0.482       | 0.0          | 0.046        | 0.492        | 0.245-0.986  | -            |
| 15       | Phenotype       | 2             | 0.981       | 0.0          | 0.005        | 0.491        | 0.299-0.806  | -            |
| 16       | Phenotype       | 2             | 0.411       | 0.0          | 0.065        | 0.685        | 0.458-1.023  | -            |
| 17       | Phenotype       | 2             | 0.920       | 0.0          | 0.470        | 1.341        | 0.604-2.976  | -            |
| 18       | Phenotype       | 1             | -           | -            | 0.194        | 7.135        | 0.368-138.388 | -            |

HLA: human leucocyte antigen, OR: pooled odds ratio, CI, confidence interval, -: not available.

shown that HLA-C*06 causes early-onset skin disease in both PsA and psoriasis and is not linked to nail or joint diseases.\(^41,42\) Therefore, the conflicting results described above may be explained by the bias of age at psoriasis onset or small sample size. Several investigators focused only on the role of HLA-C*06 with PsA susceptibility and then only presented the results of HLA-C*06, ignoring other alleles. The meta-analysis in the present study indicated that besides HLA-C*06, HLA-C*02 and *12 were also factors causing susceptibility to PsA, while HLA-C*04 was a protective factor for PsA at both allelic and phenotypic levels in all studies of the entire population. The effects of HLA-C*02 and *12 may be due to linkage disequilibrium with locus B (B27, B38, B39, B8), and more specifically to the asparagine residue at position 97 (common to B27,
Table 2 (cont.). Associations between HLA-C polymorphism and psoriatic arthritis and subgroup analyses based on quality at allelic and phenotypic levels.

| HLA-C/Cw | High quality | Moderate quality |
|----------|--------------|------------------|
|          | P       | I² (%) | OR    | 95% CI | P       | I² (%) | OR    | 95% CI | P       |
| 01 Allele | 0.474  | 0.0   | 1.123 | 0.603-2.094 | 0.714  | 0.0   | 1.117 | 0.726-1.720 | 0.614 |
| 02 Allele | 0.330  | 62.1  | 2.589 | 1.449-4.627 | 0.001  | 0.0   | 1.937 | 1.175-3.193 | 0.010 |
| 03 Allele | 0.464  | 0.0   | 0.605 | 0.376-0.972 | 0.038  | 0.0   | 0.711 | 0.509-0.992 | 0.045 |
| 04 Allele | 0.744  | 0.0   | 0.569 | 0.371-0.872 | 0.010  | 19.2  | 0.715 | 0.531-0.964 | 0.028 |
| 05 Allele | 0.368  | 0.0   | 0.777 | 0.394-1.532 | 0.466  | 0.0   | 0.558 | 0.369-0.844 | 0.006 |
| 06 Allele | 0.321  | 0.0   | 3.226 | 2.198-4.735 | <0.001 | 63.4  | 2.568 | 2.073-3.182 | <0.001 |
| 07 Allele | 0.709  | 0.0   | 0.726 | 0.534-0.988 | 0.042  | 0.0   | 0.601 | 0.478-0.755 | <0.001 |
| 08 Allele | 0.378  | 36.2  | 1.145 | 0.441-2.972 | 0.781  | 68.1  | 0.945 | 0.566-1.577 | 0.827 |
| 12 Allele | 0.603  | 0.0   | 1.291 | 0.865-1.924 | 0.211  | 4.1   | 1.803 | 1.132-2.872 | 0.013 |
| 14 Allele | 0.276  | 0.0   | 0.865 | 0.207-3.617 | 0.843  | 0.0   | 1.006 | 0.510-1.986 | 0.985 |
| 15 Allele | 0.456  | 0.0   | 1.248 | 0.400-3.890 | 0.703  | 0.0   | 0.728 | 0.376-1.410 | 0.346 |
| 16 Allele | 0.338  | 21.8  | 0.505 | 0.195-1.304 | 0.158  | 0.0   | 0.503 | 0.270-0.936 | 0.030 |
| 17 Allele | 0.111  | 0.0   | 0.269 | 0.068-1.058 | 0.060  | 0.0   | 0.611 | 0.146-2.565 | 0.501 |
| 18 Allele | 0.273  | -     | -     | -     | 0.001  | 0.0   | 1.579 | 0.838-2.978 | 0.158 |
| 01/1 Phenotype | 0.937 | 0.0   | 1.945 | 1.348-2.807 | <0.001 | 80.7  | 1.149 | 0.633-2.086 | 0.647 |
| 02/2 Phenotype | 0.451 | 0.0   | 0.627 | 0.477-0.824 | 0.001  | 69.6  | 1.040 | 0.635-1.704 | 0.877 |
| 03/3 Phenotype | 0.575 | 0.0   | 0.751 | 0.570-0.990 | 0.042  | 0.0   | 0.564 | 0.359-0.885 | 0.013 |
| 05/5 Phenotype | 0.294 | 0.0   | 1.103 | 0.819-1.484 | 0.520  | 61.9  | 0.403 | 0.210-0.773 | 0.006 |
| 06/6 Phenotype | 0.061 | 0.0   | 1.715 | 1.324-2.222 | <0.001 | 59.1  | 3.468 | 2.892-4.159 | <0.001 |
| 07/7 Phenotype | 0.825 | 0.0   | 0.640 | 0.517-0.792 | <0.001 | 632   | 0.632 | 0.404-0.988 | 0.044 |
| 12 Phenotype | 0.179 | -     | -     | -     | -     | -     | -     | -     | -     |
| 14 Phenotype | 0.079 | -     | -     | -     | -     | -     | -     | -     | -     |
| 15 Phenotype | 0.378 | -     | -     | -     | -     | -     | -     | -     | -     |
| 16 Phenotype | 0.111 | -     | -     | -     | -     | -     | -     | -     | -     |
| 17 Phenotype | 0.111 | -     | -     | -     | -     | -     | -     | -     | -     |
| 18 Phenotype | 0.273 | -     | -     | -     | -     | -     | -     | -     | -     |

HLA: human leucocyte antigen, OR: pooled odds ratio, CI: confidence interval, -: not available.

B38, B8), as the principal risk element for PsA.1 We also found that a number of genes were significantly correlated with PsA at the allelic/phenotypic level but not at the phenotypic/allelic level in whole population studies, such as HLA-C*07/*01. The discrepancy is presumably because of the multifactorial nature of PsA and the limitations of the research. Intra-study heterogeneity is important in meta-analysis. Heterogeneity can be effectively removed when stratified by quality for HLA-C*07. Moreover, sources of heterogeneity for other factors were explored using univariate meta-regression based on year of publication, size of cohort and case/control ratio. Nevertheless, they were not statistically correlated with heterogeneous...
ity. Heterogeneity may arise from the different genetic backgrounds, environmental exposure, bias for cases and controls through selection or unknown variables.

Meta-analysis is a useful strategy to improve analysis and statistical evidence by enlarging the effective sample size. To our knowledge, this is the first meta-analysis that has combined previously-published case-control studies to precisely analyze the association between HLA-C polymorphism and risk of PsA in Caucasian populations. Nevertheless, several inherent limitations of this meta-analysis should be addressed. First, we only considered reports published in English so language bias is inevitable. Studies with negative data may not have been represented because they are more difficult to publish than studies with positive data.

Second, the populations studied here were only populations of European and Middle Eastern descent. Thus, the conclusions of this study should be interpreted with caution for individuals of other ethnicities. Multi-ethnic populations should be incorporated into future studies.

Finally, we were unable to explore the possibility that results would vary in subjects of different ages, duration of disease and discrepancies in clinical characteristics.

In conclusion, the pooled results suggest a significant association between PsA and HLA-C polymorphism in populations of European and Middle Eastern descent. At the allelic level, HLA-C*02, *06 and *12 were associated with increased risk of PsA, while HLA-C*03, *04, *05, *07 and *16 had a decreased association of risk of PsA. At the phenotypic level, seven phenotypes had significant association with PsA. Positive associations were observed for HLA-C*01, *02, *06 and *12. Negative associations were observed for HLA-C*04, *14 and *15. At both allelic and phenotypic levels, HLA-C*02, *06 and *12 may contribute to susceptibility to PsA, while HLA-C*04 may confer a protective role against PsA. To further establish these relationships, future studies with larger sample sizes, and more accurate disease subgroup stratification with multi-ethnic sample groups are required.

REFERENCES

1. Bowes J, Ashcroft J, Dand N, Jalali-Najafabadi F, Bellou E, Ho P, et al. Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann Rheum Dis. 2017; 76(10): 1774-1779.
2. Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis. A systematic review and meta-analysis. Semin Arthritis Rheum. 2018; 48(1): 28-34.
3. Singh J, Sieper J, Kubica AK, et al. The Region Centromeric to HLA-C Is a Key Region for Understanding the Phenotypic Variability of Psoriatic Arthritis. ISRN Dermatol. 2014; 2014: 570178.
4. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005; 64 Suppl 2: i114-17.
5. Zink A, Thiele K, Huscher D, Listing J, Sieper J, Krause A, et al. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006; 33(1): 86-90.
6. Gladman DD, Rahman P. Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, Budd RC, et al. editors. Kelly’s Textbook of Rheumatology, 2001; 6th edition.
7. Chandran V, Bull SB, Pellett FJ, Ayearst R, Rahman P, Gladman DD. Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. Hum Immunol. 2013; 74(10): 1333-1338.
8. Winchester R, Minevich G, Steshenko V, Kibby B, Kane D, Greenberg DA, et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 2012; 64(4): 1134-1144.
9. Ho PY, Barton A, Worthington J, Plant D, Griffiths CE, Young HS, et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis. 2008; 67: 677-682.
10. Queiro R, Tejon P, Alonso S, Coto P, López-Larea C, Martínez-Borra J, et al. The Region Centromeric to HLA-C Is a Key Region for Understanding the Phenotypic Variability of Psoriatic Arthritis. ISRN Dermatol. 2014; 2014: 570178.
11. Chang YT, Chou CT, Yu CW, Lin MW, Shiao YM, Chen CC, et al. Cytokine gene polymorphisms in Chinese patients with psoriasis. Br J Dermatol. 2007; 156(5): 899-905.
12. Liao HT, Lin KC, Chang YT, Chen CH, Liang TH, Chen WS, et al. Human leukocyte antigen and clinical and demographic characteristics in psoriatic arthritis and psoriasis in Chinese patients. J Rheumatol. 2008; 35(5): 891-895.
13. González S, Braubart C, Martínez-Borra J, López-Vazquez A, Segal R, Blanco-Gelaz MA, et al. Polymorphism in MICA rather than HLA-B/C is associated with psoriasis. Hum Immunol. 2005; 64(9): 632-638.
14. Grubic Z, Perić P, Šušturk-Jeličić E, Zuneč K, Čurković B, et al. The MICA:A4 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum. 1999; 42(5): 318-319.
15. González S, Martínez-Borra J, Torre-Alonzo JC, Rodríguez Perez A, Coto E. HLA antigens in psoriatic arthritis subtypes of a Spanish population. Ann Rheum Dis. 1999; 58(5): 318-319.
16. Takkouche B, Cadarso-Suárez C, Spiegelman D. Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol. 1999; 150(2): 206-215.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414): 557-560.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-634.
19. Rahman P, Butt C, Siannis F, Farewell VT, Peddle L, Pellett FJ, et al. Association of SEEK1 and psoriatic arthritis in two distinct Canadian populations. Ann Rheum Dis. 2005; 64(9): 1370-1372.
20. Fojtiková M, Stolfa J, Novota P, Čejková P, Dostál C, Černá M. HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population. Rheumatol Int. 2009; 29(11): 1293-1299.
21. López-Larea C, Torre Alonso JC, Rodríguez Perez A, Coto E. HLA antigens in psoriatic arthritis subtypes of a Spanish population. Ann Rheum Dis. 1999; 42(5): 318-319.
22. González S, Martínez-Borra J, Torre-Alonso JC, González-Roces S, Sánchez del Río J, Rodríguez Pérez A, et al. The MICA:A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum. 1999; 42(5): 1010-1016.
23. Sokolik R, Čejbura K, Iwaszk M, Świękot JC, Korman L, Wiland P, et al. Significance of association of HLA-C and HLA-E with psoriatic arthritis. Hum Immunol. 2014; 75(12): 1188-1191.
24. Popa OM, Popa L, Dutescu MI, Bojinca M, Bojinca V, Ciocu C, et al. HLA-C locus and
genetic susceptibility to psoriatic arthritis in Romanian population. Tissue Antigens. 2011; 77(4):325-328.
25. Holm SJ, Sakuraba K, Mallbris L, Wolk K, Ståhle M, Sánchez FO. Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J Invest Dermatol. 2005; 125(4):721-730.
26. Cibulova A, Zajacova M, Fojtikova M, Stollf J, Sedova L, Čejková P, et al. The HLA-Cw*06 allele and -1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factor to psoriasis vulgaris and psoriatic arthritis in Czech population. Rheumatol Int. 2013; 33(4):915-919.
27. Queiro R, Gonzalez S, López-Larrea C, Alperi M, Sarasqueta C, Riestra JL, et al. HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. Arthritis Res Ther. 2006; 8(6):R185.
28. Gladman DD, Cheung C, Ng CM, Wade JA. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol. 1999; 60(3):259-261.
29. Szczekowska Dobosz A, Rebała K, Szczerkowska Z, Nedoszytko B, HLA-C locus alleles distribution in patients from northern Poland with psoriatic arthritis—preliminary report. Int J Immunogenet. 2005; 32(6):389-391.
30. Martin MP, Nelson G, Lee JH, Pellett F, Gao X, Wade J, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol. 2002; 169(6):2818-2822.
31. González S, Martínez-Borra J, López-Vázquez A, García-Fernández S, Torre-Alonso JC, López-Larrea C. MICA rather than MICB, TNFA, or HLA-DRB1 is associated with susceptibility to psoriatic arthritis. J Rheumatol. 2002; 29(5):973-978.
32. Martínez-Borra J, González S, Santos-Juanes J, Sánchez del Río J, Torre-Alonso JC, López-Vázquez A, et al. Psoriasis vulgaris and psoriatic arthritis share a 100 kb susceptibility region telomeric to HLA-C. Rheumatology. 2003; 42(9):1089-1092.
33. Queiro R, Moreno P, Sarasqueta C, Alperi M, Riestra JL, Ballina J. Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome and psoriatic arthritis exhibit a different immunogenetic profile. Clin Exp Rheumatol. 2008; 26(1):125-128.
34. Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, Welsh K, et al. Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology. 2002; 41(5):525-530.
35. Alenius GM, Jidell E, Nordmark L, Ran-tapää Dahlqvist S. Disease manifestations and HLA antigens in psoriatic arthritis in northern Sweden. Clin Rheumatol. 2002; 21(5):357-362.
36. Murray C, Mann DL, Gerber LN, Barth W, Perlmann S, Decker JL, et al. Histocompatibility alloantigens in psoriasis and psoriatic arthritis. Evidence for the influence of multiple genes in the major histocompatibility complex. J Clin Invest. 1980; 66(4):670-675.
37. Woodrow JC, Ilichysn A. HLA antigens in psoriasis and psoriatic arthritis. J Med Genet. 1985; 22(6):492-495.
38. Chen J, Yang F, Zhang Y, Fan X, Xiao H, Qian W, et al. HLA-A*01:01 in MHC is associated with psoriatic arthritis in Chinese Han population. Arch Dermatol Res. 2019; 311(4):277-285.
39. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardiner J, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008; 4(3):e1000041.
40. Stuart PE, Nair RP, Tsai LC, Tejesvi T, Das S, Kang HM, et al. Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Am J Hum Genet. 2015; 97(6):816-836.
41. McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. ‘MHC-I-opathy’—unified concept for spondyloarthritis and Behcet disease. Nat Rev Rheumatol. 2015; 11(2):731-740.
42. Queiro R, Tejón P, Alonso S, Coto P. Age at disease onset: a key factor for understanding psoriatic disease. Rheumatology. 2014; 53(7):1178-1185.